A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Adults 60 Through 64 Years Of Age
Latest Information Update: 18 Dec 2020
At a glance
- Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 25 Oct 2020 Results presented at the IDWeek 2020
- 27 Jul 2020 Results assessing safety, tolerability, and immunogenicity of PCV20 in adults 60-64 years of age without previous pneumococcal vaccination published in the Clinical Infectious Diseases
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.